AbbVie Agrees to Up to $2.5 Billion Deal With Germany’s Disco
AbbVie is expanding its bispecific cancer medicine push through a deal with Germany’s Disco valued at up to $2.5 billion.
AbbVie is expanding its bispecific cancer medicine push through a deal with Germany’s Disco valued at up to $2.5 billion.